NasdaqGS - Nasdaq Real Time Price USD
Kiniksa Pharmaceuticals International, plc (KNSA)
Tune into earnings calls Now streaming directly on quote pages.
24.58
+3.11
+(14.51%)
As of 9:34:01 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 5 |
| Avg. Estimate | 0.27 | 0.21 | 0.89 | 1.47 |
| Low Estimate | -0.09 | -0.06 | 0.2 | 0.35 |
| High Estimate | 0.45 | 0.47 | 1.69 | 2.65 |
| Year Ago EPS | -0.06 | -0.18 | -0.6 | 0.89 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 140.79M | 148.04M | 577.59M | 697.48M |
| Low Estimate | 137.92M | 145.99M | 566.29M | 645.71M |
| High Estimate | 145M | 150.38M | 610.21M | 732M |
| Year Ago Sales | 108.63M | 112.21M | 423.24M | 577.59M |
| Sales Growth (year/est) | 29.60% | 31.92% | 36.47% | 20.76% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | 0.01 | 0.07 | 0.13 | 0.28 |
| EPS Actual | -0.06 | -0.18 | -0.12 | 0.11 |
| Difference | -0.07 | -0.25 | -0.25 | -0.17 |
| Surprise % | -999.55% | -366.67% | -192.31% | -61.17% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0.27 | 0.21 | 0.89 | 1.47 |
| 7 Days Ago | 0.27 | 0.21 | 0.89 | 1.47 |
| 30 Days Ago | 0.27 | 0.21 | 1.03 | 1.75 |
| 60 Days Ago | 0.3 | 0.26 | 0.7 | 1.2 |
| 90 Days Ago | 0.3 | 0.26 | 0.7 | 1.2 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| KNSA | 548.00% | 218.01% | 248.45% | 65.07% |
| S&P 500 | 9.62% | 4.20% | 8.36% | 13.90% |
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 4/16/2025 |
| Initiated | Citigroup: Buy | 3/13/2025 |
| Maintains | JP Morgan: Overweight to Overweight | 11/5/2024 |
| Maintains | Evercore ISI Group: Outperform to Outperform | 10/30/2024 |
| Maintains | Wedbush: Outperform to Outperform | 7/23/2024 |
| Initiated | Wells Fargo: Overweight | 5/3/2024 |
Related Tickers
NBIX Neurocrine Biosciences, Inc.
106.15
-0.29%
AMPH Amphastar Pharmaceuticals, Inc.
24.20
-0.86%
HROW Harrow, Inc.
24.70
+0.18%
ETON Eton Pharmaceuticals, Inc.
15.96
-0.14%
CRDL Cardiol Therapeutics Inc.
1.0700
-0.93%
EOLS Evolus, Inc.
11.20
-0.97%
STX.L Shield Therapeutics plc
2.3500
0.00%
SOBI.ST Swedish Orphan Biovitrum AB (publ)
291.00
+4.23%
INDV Indivior PLC
11.62
+0.43%
AKBA Akebia Therapeutics, Inc.
2.4000
-1.23%